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MEETING REPORT
First translational ‘Think Tank’ 
on cerebrovascular disease, cognitive 
impairment and dementia
Frank C. Barone1,2* , Deborah Gustafson1,3, Howard A. Crystal1,4, Herman Moreno1,2, Mateusz G. Adamski5, 
Ken Arai6, Alison E. Baird1,2, Clotilde Balucani1, Adam M. Brickman7, David Cechetto8, Philip Gorelick9, 
Geert Jan Biessels10, Amanda Kiliaan11, Lenore Launer12, Julie Schneider13, Farzaneh A. Sorond14, 
Rachel Whitmer15, Clinton Wright16 and Zheng Gang Zhang17
Abstract and introduction to the workshop 
As the human population continues to age, an increasing number of people will exhibit significant deficits in cogni-
tive function and dementia. It is now recognized that cerebrovascular, metabolic and neurodegenerative diseases 
all play major roles in the evolution of cognitive impairment and dementia. Thus with our more recent recognition 
of these relationships and our need to understand and more positively impact on this world health problem, “The 
Leo and Anne Albert Charitable Trust” (Gene Pranzo, Trustee with significant support from Susan Brogan, Meeting 
Planner) provided generous support for this inaugural international workshop that was held from April 13–16, 2015 
at the beautiful Ritz Carlton Golf Resort in North Naples, Florida. Researchers from SUNY Downstate Medical Center, 
Brooklyn, NY organized the event by selecting the present group of translationally inclined preclinical, clinical and 
population scientists focused on cerebrovascular disease (CVD) risk and its progression to vascular cognitive impair-
ment (VCI) and dementia. Participants at the workshop addressed important issues related to aging, cognition and 
dementia by: (1) sharing new data, information and perspectives that intersect vascular, metabolic and neurodegen-
erative diseases, (2) discussing gaps in translating population risk, clinical and preclinical information to the progres-
sion of cognitive loss, and (3) debating new approaches and methods to fill these gaps that can translate into future 
therapeutic interventions. Participants agreed on topics for group discussion prior to the meeting and focused on 
specific translational goals that included promoting better understanding of dementia mechanisms, the identification 
of potential therapeutic targets for intervention, and discussed/debated the potential utility of diagnostic/prognostic 
markers. Below summarizes the new data-presentations, concepts, novel directions and specific discussion top-
ics addressed by this international translational team at our “First Leo and Anne Albert Charitable Trust ‘Think Tank’ VCI 
workshop”.
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Workshop participant presentations
Philip Gorelick (Michigan State University, USA) started 
the meeting by commenting on vascular risks for cognitive 
impairment with a historical perspective in order to help 
us see our way forward
It has long been believed that traditional cardiovascular 
risk factors for stroke are risk factors for vascular forms of 
cognitive impairment, as well as late-onset dementias and 
Alzheimer’s disease (AD). Epidemiologic observational 
studies have supported this, and over time it has been 
shown that traditional cardiovascular risk factors are also 
risk factors for Alzheimer’s disease (AD). At this time this 
finding was largely unexpected. Reaching this knowledge 
plateau was delayed in part as a major operational definition 
of AD in the 1980s that essentially excluded the presence 
of traditional CVD risks [1]. Over time neuropathologi-
cal-clinical translational studies caught up with hypoth-
esis generation and showed that many cognitively impaired 
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persons in later life had vascular lesion neuropathology that 
might also explain existing cognitive impairment [2–4]. The 
discovery that shared cardiovascular risks and mechanistic 
pathways were linked in both vascular and “neurodegen-
erative” disorders resulting in later life dementia supported 
this more contemporary thinking. This has led us to bet-
ter define specific upstream pathophysiologic mechanisms 
contributing to neurovascular changes contributing to 
the cognitive dysfunction phenotype. We are encouraged 
by large scale epidemiological studies on incidence and 
prevalence of longitudinal cognitive function that show 
maintenance of cognitive vitality over time, which may be 
due at least in part to better control of or reduced cardio-
vascular risks. However, clinical trials of common cardio-
vascular risks such as hypertension, diabetes mellitus, and 
lipid disorders have not consistently shown clear concord-
ance. Therefore, one must keep in mind that although the 
longitudinal epidemiological studies may suffer from con-
founding, they have the advantage of long-term follow-up 
which could begin as early as midlife. Also, cardiovascular 
preventive measures to reduce risk may need to be admin-
istered earlier in life and sustained over time for there to 
be a significant benefit at reducing the evolution of cogni-
tive impairment to dementia. As we move forward in the 
field, there remain gaps in our understanding of molecu-
lar and cellular mechanisms and biomarkers for vascular 
causes of cognitive impairment and dementia. Many ques-
tions exist. For example: what are the molecular or cellu-
lar mechanisms of factors such as lipids, cell types related 
to innate and adaptive immunity, the blood brain barrier, 
blood flow, the role of traditional cardiovascular risks that 
are implicated in causation? Specific strategies that lead us 
to answers of important questions about vascular causes of 
cognitive disorders include: (1) development of a research 
network for the study of vascular mechanisms and risks for 
cognitive phenotypes as we age, (2) a scientific focus that 
includes basic pathophysiologic mechanisms and transla-
tional approaches, study of high resolution neuroimaging-
clinical-neuropsychological-neuropathological outcomes, 
and development of multi-modal prevention and treatment 
studies, and (3) a lifecycle focus that includes provision of 
long-term studies including midlife and late life, as the ben-
efits and adversities associated with prevention may result 
in different outcomes depending on different life stages. He 
emphasized that our mechanistic focus will need to remain 
upstream in order to intervene and halt downstream dam-
age and dementia progression effectively.
Deborah Gustafson (SUNY Downstate Medical Center, USA) 
suggested that published data support AD as a vascular 
disease
She summarized relevant epidemiological studies report-
ing that vascular risk factors, such as being overweight 
and obesity, hypertension, high blood levels of choles-
terol, and type 2 diabetes mellitus, can increase risk for 
a clinical diagnosis of late-onset, sporadic AD [5]. The 
importance of CVD risk factors in AD has been con-
sistently reported in the epidemiological literature for 
over 30  years, and global awareness increases. Vascular 
pathology in both brain and periphery is associated with 
AD, and new genetic findings enrich the evidence base 
for vascular factors in AD and involvement of peripheral 
metabolism in health of the brain [6]. Why are vascular 
factors associated with risk for a late life neurodegenera-
tive disorder, such as AD? It was proposed that neurode-
generative events in AD, involving amyloid and tau, are 
vascular. The biology, systems and genes, as well as the 
neuropathology and imaging modalities used to diagnose 
the disorder, support this. Appreciating the breadth of 
what AD is explains and links the epidemiology, neuropa-
thology, and clinical manifestation of this disorder of lat-
est life–vascular AD. Many lines of evidence underscore 
vascular risk in AD, originating from neuropathological, 
imaging, mechanistic, genetic, clinical and epidemiologic 
studies. Interactions between brain and periphery, and 
the important role of the blood brain barrier, support the 
role of vascular factors. Accelerated progression of atro-
phy in AD measured using serial MRI is associated with 
vascular risk factors. Cerebral hypoperfusion, resulting 
from atherosclerosis and hypertension, increases AD 
risk. As such AD augments itself via multiple mecha-
nisms. This is not to exclude other vascular and/or neu-
rodegenerative events occurring alongside AD [7–9]. 
Observations of multiple ‘causes’ of AD due to neuritic 
amyloid plaques, Aβ fragments, neurofibrillary tangles, 
amyloid angiopathy, leukoariosis, atrophy, decreases in 
synaptic plasticity, altered dendritic spines, as well as 
apoptotic events could also point to a common underly-
ing vascular pathology with heterogeneous manifestation 
due to neurovascular coupling. From clinical and epide-
miological realms, vascular AD explains AD progression 
with corresponding changing symptom profiles, and even 
changing diagnoses over time. It is common in clinical 
and epidemiological studies for an individual to initially 
present with mild cognitive impairment, and be ‘normal’ 
at the next visit; or for a diagnosis of ‘AD plus stroke’, to 
become ‘probable AD’ over time, due to the slow pro-
gressive course of disease. The contribution of stroke in 
vascular AD is an obvious accelerator of dementia pro-
cesses, and follows earlier Nun study [2] observations. 
Vascular AD may explain heterogeneous biomarker pro-
files (cerebral spinal fluid; CSF and imaging) and relative 
lack of specificity for those with clinical AD. From the 
epidemiology, vascular AD also explains observations of 
different vascular risk factor profiles for AD across popu-
lations with different magnitudes of effect, yet clinical 
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AD occurring in all. This is also a product of differential 
susceptibility due to environment, lifestyle, and genetic 
background, as well as differences in specific times of 
life studied. Vascular AD explains the often transient or 
treatable declines in cognition observed in type 2 dia-
betes, human immunodeficiency virus/acquired immu-
nodeficiency syndrome (HIV/AIDS), cancer, and other 
medical conditions, that have been said to ‘look like’ AD, 
but due to their transience and/or altered imaging or CSF 
biomarker profiles may be ‘something else’. Thus, AD is 
CVD based related to two fundamental elements of brain 
biology: APP and neurovascular coupling. These two ele-
ments align to illustrate why an amyloid-based model of 
AD is vascular based, and to support neurovascular cou-
pling as an underlying mechanism for AD. This evidence 
advances the forum for scientific discourse related to 
AD neurodegenerative processes to include CVD and its 
role(s) in dementia. She concluded by emphasizing again 
that ‘AD is Vascular AD’.
Geert Jan Biessels (Brain Center Rudolf Magnus, The 
Netherlands) described advances in detecting dementia 
vascular burden using higher resolution imaging 
approaches that extend significantly beyond conventional 
lesion detection
Previous autopsy studies have identified vascular pathol-
ogy in the majority of patients with dementia and also in 
those with a clinical diagnosis of AD. Detection of this 
vascular pathology during life mainly relies on magnetic 
resonance imaging (MRI). The typical MRI manifesta-
tions of vascular pathology in the brain—in particular 
parenchymal lesions linked to small vessel disease—are 
common and are clearly associated with dementia risk. 
In fact, both in research and clinical practice these MR 
lesions have almost become our conceptual equivalent 
of small vessel disease. However, small vessel disease 
lesions represent an end-stage, are not sufficiently spe-
cific to understand disease processes and actually do 
not reflect abnormalities of the small vessels themselves. 
Moreover, small vessel disease lesion-burden alone often 
relates poorly to cognition in individual patients. Here 
he highlighted novel approaches to zoom in on novel 
imaging manifestations of small vessel disease and on 
some of the vascular abnormalities that may actually 
cause small vessel disease lesions, using high field 7T 
MRI. He showed how 7T MRI now enables us to study 
abnormalities in intracranial vessel structure and func-
tion with unprecedented detail [10–12]. These novel 
techniques are now being implemented in further studies 
to unravel the aetiology of small vessel disease. Moreo-
ver, I demonstrated that cortical microinfarcts, a very 
common form of ischemic brain injury related to cog-
nitive decline and dementia, can now be detected with 
7T in  vivo [13]. The delineation of the imaging features 
of microinfarcts on 7T MRI now also helps to recognize 
them on 3T MRI, allowing a more rapid implementation 
of microinfarcts as a novel marker in vascular cognitive 
impairment research. We have already seen in a collabo-
rative project with the team of Dr Chen from Singapore 
that these lesions do have specific cognitive correlates in 
a memory clinic population [14]. He also discussed work 
on MRI and MR-post processing approaches that better 
reflect the functional burden of small vessel diseases, also 
in individual patients. The potential of so-called ‘lesion 
symptom mapping’ was highlighted. This takes location 
of small vessel disease lesions, also in relation to main 
white matter tracts into account [15]. In addition, the 
potential of advanced brain network analyses with diffu-
sion tensor imaging in the context of vascular cognitive 
impairment was discussed [16]. These developments in 
MRI technology and image analysis have great poten-
tial to improve our understanding of the aetiology of the 
vascular burden in dementia, will help to make a more 
accurate diagnosis, and will ultimately contribute to the 
development of targeted treatment.
Howard Crystal (SUNY Downstate Medical Center, USA) 
presented data from his collaborative work on Vascular 
Health and Cognition in Women with HIV
Highly active antiviral therapy (HAART) has been widely 
available in the United States for nearly 20  years. Most 
studies report that with HAART the prevalence of HIV-
associated dementia is markedly decreased, but milder 
forms of cognitive impairment remain common with 
prevalence estimates as high as 50  % [17]. As vascular 
health is associated with preserved cognition [18], and 
because both HIV and HAART can be vasculopathic, 
he hypothesized that vascular health would account for 
much of the variance in cognitive scores, and that vas-
cular dysfunction would be associated with changes on 
volumetric MRI. Women from the Brooklyn site of the 
women’s interagency HIV study had measures of both 
large vessels (e.g., carotid intima media thickness and 
extracranial vessel velocities) and small vessels (e.g., pul-
satility index of intracranial arteries and metrics from 
retinal photographs). 3T MRI with diffusion tensor imag-
ing (DTI) sequences were obtained at New York Univer-
sity and analyzed by members of the Stebbins laboratory 
at Rush. Neuropsychological batteries were administered 
every 2  years, and summary measures of HAART-use 
over up to 20  years were obtained. High quality MRI 
and retinal photographs were available on 34 HIV-
infected and 21 HIV-uninfected, age-matched women. 
He reported the effects of HIV-infection and HAART on 
vascular health, cognition, and MRI; the effects of vas-
cular health on cognition, and the associations between 
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vascular health and MRI volumetrics, and between MRI 
and cognition. Initial analyses indicated that increas-
ing arterial dimension was associated with higher vol-
umes, but increasing venous dimension was associated 
with lower volumes. According, he explored a novel 
measure—fractal dimension ratio (i.e., the arterial frac-
tal dimension divided by venous fractal dimension)—as 
a summary measure. Significant partial correlation coef-
ficients between fractal dimension ratio and 4 of the 6 
volume measures and 4 of the 5 selected white matter 
integrity measures. In contrast the partial correlations 
between arterial or venous fractal dimension and the 
MRI measures were rarely significant. He suggested that 
retinal fractal dimension may be a surrogate marker of 
brain small vessel disease.
Alison E. Baird (SUNY Downstate Medical Center, USA) 
discussed recent and near‑future advances in nucleic 
acid‑based diagnosis of stroke that also have potential 
for use in VCI
Here the rationale for the use of blood-based nucleic 
acid biomarkers to advance stroke diagnosis, treatment 
and prognosis determination was provided [19, 20]. She 
described how stroke is a leading cause of death and dis-
ability in adults, but at present, treatment for ischemic 
stroke reaches only a small percentage of patients. This 
is because of the very short time window for treatment 
and the time-consuming evaluation involved. She high-
lighted the intense efforts that are underway to find novel 
approaches to expedite stroke diagnosis and treatment 
demonstrating the strong rationale for the use of blood-
based nucleic acid biomarkers to advance stroke diag-
nosis, as well as prognosis and prediction of VCI [21]. 
It was also reported that so far, no blood marker has 
emerged for clinical application in acute stroke manage-
ment during the time window for treatment. Messenger 
ribonucleic acid markers have been identified in genomic 
profiling of circulating leukocytes that show promise 
for stroke detection and classification but technological 
issues are hindering the application of these microarray-
derived results [22–24]. The sensitivity and specificity of 
transcript panels for ischemic stroke detection require 
further investigation, along with the time course of 
expression changes and which leukocyte subsets are the 
predominant sources of the gene expression changes. 
She then described the efforts currently underway to 
develop novel platforms for stroke diagnosis to meet the 
criteria for effective treatment within the narrow time 
window mandated by the FDA (<3  h) and to expedite 
further research studies into the application of the tran-
script panels for stroke diagnosis. Her collaborators, Dr. 
Soper and his group, are developing a lab-on-a-chip tech-
nology that provides the quantitative measurement of 
multiple transcripts in a turn-around-time of 15–22 min. 
The processing steps involve cell counting, cell subset, 
ribonucleic acid extraction and single pair fluorescence 
resonance energy transfer readout to provide an absolute 
copy number of as many as 30 transcripts. The technol-
ogy is independent of polymerase chain reactions and 
uses chips the size of a quarter that cost a few pennies. 
Meanwhile her group has been performing clinical stud-
ies in tandem to address issues of transcript quantita-
tion, transcript optimization, determination of expected 
expression levels in stroke and control condition and 
determination of which leukocyte subsets to employ [25]. 
This work is showing how nucleic acid blood-based bio-
markers coupled with new analytical tools and can serve 
as an attractive platform for managing stroke-related dis-
eases in the emergency and outpatient clinical settings 
that might also be extended to VCI [26].
Mateusz G. Adamski (Jagiellonian University, Poland) 
described the potential for circulating blood cells 
as potential biomarkers and active players in the 
development of VCI
VCI is recognized to be associated with the develop-
ment of vascular diseases and subsequent compromise 
of the blood brain barrier (BBB) permeability. New roles 
of circulating blood immune cells, representing both 
innate and adaptive responses, have been recently identi-
fied to play a major role in the pathomechanism of two 
major VCI risk factors: stroke and hypertension. These 
new findings were very intriguing as they challenged the 
notion that due to anatomical and physiological limita-
tions, full immune response cannot develop in central 
nervous system. These limitations included: early for-
mation and development of BBB, lack of cerebral lym-
phatic vessels, inefficiency of microglia and astrocytes for 
antigen presentation to T cell lymphocytes, high rate of 
apoptosis in cells crossing BBB, assumption of the pas-
sive function of neurons and short time for the adaptive 
immune response to develop especially in acute stroke. 
Thus, selected results from clinical and experimental 
studies were presented to show that cells represent-
ing both innate and adaptive immune systems as well as 
bridge cells—having features of both adaptive and innate 
immunity—contribute to the development of VCI risk. 
First, the results on the role of invariant natural killer 
T cells and granulocytes, both representatives of innate 
immune system, in experimental and clinical stroke were 
presented. Immunomodulation of invariant natural killer 
T cells was shown to be protective in mice stroke model 
[27]. Expression of 3-gene cluster in CD15 granulocyte 
in acute ischemic stroke patients was shown to be highly 
sensitive (89 %) and specific (67 %) in classifying stroke 
(unpublished). Second, the role of several populations 
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of CD4 T cells and B cells, representatives of adaptive 
immune system, from clinical and experimental stroke 
studies was presented. Stroke clinical studies showed dif-
ferences in function and frequencies of several subsets of 
circulating T- [28, 29] and B-lymphocytes [30]. Experi-
mental stroke studies showed that T regulatory lympho-
cytes induce endothelial dysfunction and increase infarct 
size [31] and that depletion of IL-21 producing T cells 
improves stroke outcome [32]. Third, the role of natural 
killer T cells and γδT cells, representatives of bridge cell 
populations, was presented in stroke and hypertension. 
Clinical stroke induced changes in absolute numbers of 
both natural killer T cells and γδT cells, with hyperten-
sion being the strongest factor causing γδT cell reduc-
tion [33]. Experimental study showed that subsequent to 
stroke, γδT cells infiltrate brain and secret IL-17A—detri-
mental for ischemic brain [34]. Other participants at this 
Inaugural workshop highlighted the importance of VCI 
in the development of dementia and stressed the need to 
identify underlying mechanisms responsible for the dis-
ease. Therefore, circulating blood cells can be involved 
in diverse and pathological vascular mechanisms and are 
promising potential target opportunities as biomarkers 
and active players in the context of VCI.
Clotilde Balucani (SUNY Downstate Medical Center, USA) 
discussed her collaborative research exploring cognitive 
performance and cerebral hemodynamics in bilateral 
asymptomatic carotid stenosis
The work was conducted with Mauro Silvestrini, MD 
(Neurological Clinic, Marche Polytechnic University, 
Ancona, Italy). Few studies have highlighted the associa-
tion between severe carotid atherosclerosis markers (i.e. 
increase in carotid intima–media thickness and carotid 
plaques) and an increased risk of cognitive impairment, 
presence of silent cerebral infarcts, white matter lesions, 
and reduced parietal grey matter. Here she evaluated 
cognitive performance in subjects with bilateral asymp-
tomatic carotid stenosis compared to subjects with uni-
lateral asymptomatic carotid stenosis and to subjects 
with no carotid stenosis and to explore the relationship 
between cognitive performance and cerebral hemody-
namics status. Further longitudinal cognitive and hemo-
dynamic performance was measured in subjects with 
bilateral and unilateral asymptomatic carotid stenosis. 
Cerebral hemodynamics status was assessed using the 
transcranial Doppler-based breath-holding index test. 
The neuropsychological investigation included tests 
for exploring the left and right brain functions. In the 
longitudinal cohort the cognitive status was evaluated 
using the Mini-Mental State Examination at baseline 
and at 3  years. The study included 333 patients. Sub-
jects with bilateral and unilateral asymptomatic carotid 
stenosis were significantly more likely to have cogni-
tive dysfunction compared to subjects with no carotid 
stenosis. Further, there was a statistically significant 
association between cognitive dysfunction and cerebral 
hemodynamic impairment resulting from the carotid 
stenosis. In the group of 159 patients followed-up at 
3 years, the risk of cognitive impairment increased pro-
gressively from patients with bilaterally normal to those 
with a bilaterally abnormal breath-holding index. These 
findings support the contributing role of carotid ste-
nosis in the development of cognitive impairment. The 
evaluation of the hemodynamic status, besides provid-
ing insights about the possible mechanism behind the 
development cognitive dysfunction in otherwise asymp-
tomatic carotid disease, may be of help for the individu-
ation of subjects deserving earlier and more aggressive 
treatments.
Rachel Whitmer (Kaiser Permanente Northern California, 
USA) discussed diabetes mellitus and dementia 
experimental model work designed to better 
understanding vascular contributions to brain aging
Although vascular risk factors are associated with 
increased risk of dementia and markers of accelerated 
brain aging, the mechanisms and timing of influence 
are not clearly delineated. Diabetes mellitus, a metabolic 
condition with numerous vascular sequelae is rapidly 
increasing in incidence worldwide. While it is estab-
lished that those with type 2 diabetes have twice the risk 
of dementia and cognitive impairment, less is known 
regarding how the characteristics of this disease impact 
brain health. Specifically, the role of diabetes treatment, 
micro/macrovascular complications and long-term gly-
cemic control is little understood. Those with type 1 
diabetes, a disease with onset typically in childhood 
or adolescence and with immediate insulin treatment, 
are now living to old age, whether these individuals are 
at higher risk of age-associated neurodegenerative dis-
ease has not been studied. We have been following over 
20,000 elderly individuals with diabetes mellitus since 
1994 in the Kaiser Permanente Northern California Dia-
betes Registry. Here recent findings on long-term glyce-
mic control and vascular complications of diabetes on 
dementia risk were presented with a primary objective 
of identifying diabetes-associated characteristics which 
impact dementia and how this translates to the general 
population and better elucidation of potential vascular-
brain mechanisms. A newly launched NIH funded Study 
of Longevity in Diabetes (SOLID) study is now following 
elderly patients with type 1 diabetes to ascertain the cog-
nitive aging signature of this disease and to identify risk 
and protective factors for cognitive impairment in this 
population newly entering old age.
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Amanda Kiliaan (Donders Institute for Brain, Cognition 
and Behaviour, The Netherlands) presented on the 
impact of diet on cerebral circulation, neuronal integrity 
and cognition in mouse models for vascular risk factors 
in AD
The important role of diets and healthy lifestyle as 
preventative of vascular diseases is widely accepted. 
Recently, the Mediterranean diet (e.g., containing poly-
unsaturated fatty acids as important components) has 
been shown in several prospective world-wide studies 
to be inversely associated with CVD and to be a strong 
protective factor against hypertension, obesity, and AD 
[35–38]. Dietary lipids are beginning to be recognized 
for their direct actions on synaptic function and cogni-
tive processes. However, diets high in saturated fat are 
becoming notorious for reducing molecular substrates 
that support cognitive processing and increasing the risk 
of neurological dysfunction in both humans and animals. 
Previous and new preliminary data in mice models of AD 
and vascular impairment show that diet (i.e., containing 
several components of the Mediterranean diet) is able to 
inhibit/reverse the early functional connectivity reduc-
tion and impairment in cerebral blood flow [39–41]. Both 
parameters are apparent already before cognitive decline. 
Thus, diet changes may provide preventive strategies in 
very early, non-symptomatic phases of AD. Recent focus 
is therefore on the early, asymptomatic phase of the dis-
ease especially on the cardiovascular-metabolic risk fac-
tors including atherosclerosis, hypertension, obesity and 
Type II Diabetes that can be modified by changes in diet 
lifestyle. In order to validate potential therapeutic targets 
several transgenic and non-transgenic animal models 
have been developed to elucidate the mechanistic aspects 
of AD. Mostly, transgenic rodent models over-express-
ing human amyloid β (Aβ) precursor protein (β-APP) 
and mutant forms of tau have become important tools 
to study the pathogenesis of AD [42], and to test new 
therapeutic agents. Nevertheless, none of the transgenic 
models of AD recapitulate fully all of the pathological 
features of the disease and they don’t take into account 
the effect of the most important aspects of human AD, 
namely risk factors in aging, CVD, and gender. It should 
be mentioned that sex is an important risk factor for 
both AD and stroke, as both conditions appear to affect 
women more than men [43, 44]. In contrast, male sex is 
considered a risk factor for mixed vascular-AD demen-
tia [45]. The sex factor is often ignored when designing 
experimental studies investigating stroke-related vascular 
disorders and AD. So-called mixed dementia, with post-
mortem pathological evidence for both cardiovascular 
disease and AD, is now thought to be much more com-
mon in the elderly than any of the ‘pure’ forms of demen-
tia. Recent advances in imaging techniques now allow 
for the in vivo visualization of parameters such as brain 
volume and connectivity (MRI), gray and white matter 
integrity (MRI-DTI) and blood perfusion (MRI arterial 
spin labelling). In dementia and cardiovascular disease, 
imaging has provided valuable differential diagnostic 
information, for example demonstrating the atrophy pat-
terns and Aβ deposits typical for AD [46] and the lesions 
and network reorganizations associated with cardiovas-
cular disease [47]. However, none of these animal studies 
have examined neuroimaging parameters, although they 
have mainly focussed on elucidating the bidirectional 
interaction between β-APP/Aβ and ischemic injury and 
the potential role of inflammation. As advanced neuro-
imaging techniques are now available for small animals 
such as mice [48, 49], it is feasible to gain more insight 
into AD pathology and the role of cerebrovascular dis-
orders. There is a significant concern that most animal 
models for AD are showing translational failure and that 
improved translational models using translationally-vali-
dated diagnostic tools should be developed and utilized.
Herman Moreno (SUNY Downstate Medical Center, USA) 
described the divergent pathologies Tau‑ and Aβ‑42 have 
on the functioning of entorhinal—hippocampal circuits
Here he used the electrophysiological measurements in 
hippocampal slices from AD mouse models. The entorhi-
nal cortex is the gateway into the hippocampal circuit 
and is affected early in AD. AD itself is defined by a co-
occurrence of tau and amyloid-related pathologies. How 
the co-occurrence of these pathologies in the entorhinal 
cortex affects the electrophysiological profile of the hip-
pocampal circuit remains unknown. He answered this 
question by performing detailed electrophysiological 
analyses of the circuit in three mouse models that selec-
tively express in the entorhinal cortex the genetically-
induced disease-causing mutations in mice expressing 
mutant β-APP (to produce increased oligomeric Aβ-42 
peptides as in AD) or in human Tau, or both mutant 
β-APP and human Tau. Our findings confirm that β-APP 
and Tau expression produce contrasting electrophysi-
ological effects. Entorhinal cortex-β-APP expression 
caused spontaneous network hyperexcitability, in the 
superficial layers of the entorhinal cortex. Additionally, 
pyramidal cells of the subiculum, which are monosynap-
tically connected to entorhinal cortex, showed decreased 
miniature excitatory postsynaptic current amplitude, 
which may represent a synaptic homeostatic response 
to increased neuronal activity at the entorhinal cortex 
level of mice expressing β-APP. Human Tau expression 
was associated with an effective decrease in induced 
synchronous discharges, observed in the entorhinal 
cortex-hippocampal circuit and no significant changes 
in subicular neuronal miniature excitatory postsynaptic 
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current amplitude. Entorhinal cortex-β-APP expres-
sion resulted in an increase in the paired-pulse facilita-
tion normally seen in the entorhinal cortex-subiculum 
synapse, while entorhinal cortex—human Tau expres-
sion resulted in a decrease. In humans, amyloid pathol-
ogy in the entorhinal cortex occurs on the background 
of Tau pathology, therefore oligomeric Aβ-42 peptides 
were applied in the entorhinal cortex-hippocampal 
slice and produced an acute increase in both spontane-
ous and evoked synaptic events in subicular neurons of 
normal wild-type mice. Human Tau-expressing mice did 
not respond to oligomeric Aβ-42 peptides. Next, mice 
expressing mutations of both mutated β-APP and human 
Tau in the entorhinal cortex were studied. The elec-
trophysiological profile in the mice co-expressing both 
mutant β-APP and human Tau shows that human Tau 
has a dominant effect, generally dampening the excita-
tory effects of β-APP. Thus, these data suggest that the 
occurrence of epileptiform activity in human AD may 
depend in the ratio of mutant β-APP and resultant oli-
gomeric Aβ-42-to Tau-induced pathologies. He is now 
extending this work to investigate the changes that can 
be produced by acute stroke in the background of β-APP- 
Aβ and Tau pathology, and is also characterizing the 
functional presynaptic changes produced by Tau pathol-
ogy under these conditions.
Zheng Gang Zhang (Henry Ford Hospital, USA) presented 
new data on how stroke exacerbates neurovascular 
and white matter damage in diabetic rats
Diabetes is a common metabolic disease in the aged 
population, which leads to an increase of stroke inci-
dence and slower neurological recovery. His recent data 
demonstrates that middle age rats with type II diabetes 
exhibit spatial learning deficits. Immunostaining analysis 
showed the presence of microvascular leakage and loss 
of axons and mature oligodendrocytes in the hippocam-
pus. Focal cerebral ischemia exacerbated neurological 
outcomes and learning deficits during stroke recovery 
in middle-age diabetic rats compared to age-matched 
ischemic rats without diabetes. Stroke increased vascu-
lar leakage and reduced oligodendrocytes and myelinated 
axons within the hippocampus of diabetic rats. However, 
stroke did not increase stroke-induced infarction in dia-
betic rats. In addition, he found that diabetes activates 
the toll-like receptor/IL-1R-associated kinase signaling 
pathway in cerebral endothelial cells and that blocking 
this signaling pathway with a tetrapeptide N-acetyl-seryl-
aspartyl-lysyl-proline (AcSDKP) substantially reduced 
neurovascular and white matter damage and improved 
neurological outcome including learning deficits after 
stroke.
Ken Arai (Harvard Medical School, USA) discussed the roles 
of oligodendrocyte precursor cells in cerebral white matter 
under physiological and pathophysiological conditions
White matter damage is a clinically important aspect of 
several CNS diseases including stroke or vascular demen-
tia. For example, increased white matter lesions are well 
known to be negatively correlated with cognitive func-
tion [50]. White matter primarily consists of axonal bun-
dles ensheathed with myelin by mature oligodendrocytes, 
and plays an important role in passing signals between 
different areas of gray matter. However, compared to 
the mechanisms of neuronal injury in gray matter, white 
matter pathophysiology such as oligodendrocyte death 
and myelin damage remains relatively understudied and 
poorly understood. During development, oligodendro-
cyte precursor cells migrate from the ventricular zone to 
their destination and then differentiate into mature oli-
godendrocytes to form myelin sheaths. Although myeli-
nated tracts are formed early in life, renewal of myelin 
and oligodendrocyte continues throughout most of the 
adult life. Residual oligodendrocyte precursor cells may 
also play an important role in the endogenous mecha-
nisms of white matter repair and renewal after white mat-
ter damage [51, 52]. Here he discussed oligodendrocyte 
precursor cell functioning in cerebral white matter under 
both physiological and pathophysiological conditions. 
New data indicates that oligodendrocyte precursor cells 
are important for white matter remodeling and repair in 
the mouse model of prolonged cerebral forebrain hypop-
erfusion. Notably, compensative responses in these pre-
cursor cells were dampened by ageing. Compared to 
young mice (2–3  months old), a pro-survival “cyclic 
adenosine monophosphate response element-binding 
protein” signaling was suppressed in middle-aged mice 
(8–10  months old), which disturbed precursor cell dif-
ferentiation (i.e. reduced oligodendrogenesis) after white 
matter injury. Since activating this pro-survival signal-
ing by cilostazol was supportive for white matter func-
tion against hypoxic stress even in middle-aged mice, the 
cyclic adenosine monophosphate response element-bind-
ing protein signaling would be a potential therapeutic 
target for white matter-related diseases [53]. In addition, 
another important aspect of oligodendrocyte precursor 
cells was discussed. These precursor cells might not be 
“mere progenitors” for mature oligodendrocytes. Rather, 
these cells may communicate closely with neighbor-
ing cells to actively maintain white matter homeostasis. 
Using pharmacological and genetic approaches he dem-
onstrated that precursor cell-derived factors regulate 
the integrity of the blood brain barrier in cerebral white 
matter. For example, under normal conditions, precus-
sor cells secret TGFβ that strengthens blood brain barrier 
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integrity [54]. However, under pathological conditions, 
these cells can “attack” or damage the blood brain barrier 
by secreting matrix metalloproteinases, which eventually 
leads to white matter/myelin dysfunction [55]. Although 
oligodendrocyte precursor cells are one of the major cell 
types in adult white matter, their roles are still mostly 
unknown. Therefore, a deeper understanding of OPC 
roles after white matter damage can be expected to lead 
us to novel therapeutic approaches for CVD and VCI.
David Cechetto (Western University, Canada) provided a 
detailed discussion of pathological mechanisms and the 
therapeutic potential of co‑morbid models that use 
combined vascular plus AD risk factors
Clearly, CVD and vascular risk factors exacerbate cogni-
tive decline in AD. Animal models have now provided 
considerable insight into the interaction of vascular risk 
factors such as stroke or diabetes and high levels of amy-
loid in the brain. Here vascular risk models included the 
use of small striatal strokes in rats consuming high fat and 
caloric diets. In addition, these risks were combined in 
AD models that involved the use of transgenic AD mice or 
rats that received injections of Aβ into the cerebral lateral 
ventricles. Outcomes measured include cognitive deficits, 
AD-like pathology, neuroinflammation, oxidative stress, 
measures of gap junction proteins, membrane raft proteins 
and glanglioside levels, brain infarct size, hippocampal 
progenitor cell proliferation and migration, neurovascular 
unit disruption, MRI imaging of structural changes, and 
cerebral blood flow changes using CT imaging. Typically, 
these outcome measures exhibit an enhanced pathologi-
cal change when cerebrovascular manipulation or vascular 
risk factors are combined in AD models or with cerebral 
ventricular Aβ. Some of these changes in outcome occur 
early in the cascade of events (i.e., precede major neurode-
generative changes), and thus can be examined as possible 
therapeutic targets for intervention to prevent subsequent 
pathological changes and cognitive decline.
Frank C. Barone (SUNY Downstate Medical Center) 
described a translational rat model of VCI that combines 
the hypertension and carotid artery stenosis risk factors 
known to produce VCI in man
VCI is associated with CVD and involves reduced fore-
brain perfusion. Symptoms and signs of VCI include 
deficits in executive function, working memory and sig-
nificant problems in gait/balance. Our current limited 
understanding of VCI mechanisms emphasizes our need 
for animal models that represent these factors, symp-
toms and pathological changes exhibited by VCI in man 
[56–59]. Here hypertension (i.e., to mimic small vessel 
disease that can significantly impair cognition in man) 
and reduced forebrain hypoperfusion (i.e., using bilateral 
carotid artery stenosis to mimic the consequences of 
carotid atherosclerosis) were incorporated together in 
order to create a relevant model for future VCI transla-
tional research. Bilateral common carotid artery stenosis 
surgery (i.e., guided by reduced forebrain microvascular 
perfusion) or sham surgery was performed in spontane-
ously hypertensive rats (SHR). SHR were evaluated on a 
series of neurological (gait, balance and sensory-motor) 
and cognitive (active place avoidance; APA) tests. Several 
separate experiments have been conducted to establish 
reliability and validation of the developed model. His-
tological measurements of corpus callosum fiber tract 
myelin loss, microvascular changes and increased micro-
glia and astrocytes were measured to investigate if brain 
changes were similar to those observed in human VCI. 
SHR with stenosis surgery exhibited a persistent decrease 
in forebrain perfusion resulting in significant deficits in 
APA learning and gait/balance occurring within 3 weeks 
and persisting for over >3 months. Stenosis SHR do not 
learn to avoid entry into a shocked location on a moving 
APA arena, while similar total path/movement is trave-
led by both groups in the test environment. Stenosis SHR 
deficits were not related to differences in general motor 
activity, sensory-motor deficits, peripheral cardiovascular 
measures or body weight. In the corpus callosum, stenosis 
produced significant myelin loss and increases astrocyte 
and microglia activation and proliferation. Thus, carotid 
stenosis in the hypertensive rat results in cognitive and 
behavioral changes that mimic human VCI [48, 60] and as 
seen in other related rat models [61, 62]. The APA learn-
ing paradigm requires complex cognitive control and is 
a sensitive detector of VCI-like cognitive deficits. Thus, 
this “carotid stenosis plus hypertension model” combines 
important cerebrovascular risk factors that mimic known 
contributing conditions and produces symptoms analo-
gous to human VCI. It is expected to be an important tool 
for preclinical studies that can probe VCI pathophysiol-
ogy, mechanisms and intervention. Plans are to use the 
model to investigate therapeutic interventions that reduce 
microvascular and brain inflammation and myelin loss, 
promote restorative changes and to evaluate relevant bio-
markers. Ongoing work includes MRI and positron emis-
sion tomography imaging and circulating molecular and 
cellular biomarker research.
Julie Schneider (Rush University Medical Center, USA) 
discussed how CVD is an important determinant of AD 
dementia and that impairment in multiple cognitive 
domains occurs in aging
Although CVD pathology is very common in aging its 
associations with Alzheimer’s disease (AD) dementia 
and with specific cognitive domains is not completely 
understood. She investigated the role of small vessel 
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(arteriolosclerosis and cerebral amyloid angiopathy) and 
large vessel (atherosclerosis) diseases and also micro and 
macro brain infarctions that occurred in AD demen-
tia patients including several domains of their cognitive 
impairment. Over 1000 older persons without dementia 
from 2 longitudinal clinical-pathologic studies of aging, 
the Rush Memory and Aging Project and the Religious 
Orders Study, all undergo annual clinical evaluations. 
After death, a clinician reviews all data, blinded to neuro-
pathologic information to establish a final clinical diagno-
sis. Neuropathologic examinations were also blinded to 
clinical data and providee standardized measures of each 
CVD pathology. The association of each type of CVD 
with the odds of AD dementia and cognitive domains 
was examined using logistic and linear regression mod-
els. Significant CVD pathology is a very common occur-
rence in the brains of older persons (i.e., present in >75 % 
of participants and commonly co-occurs with AD pathol-
ogy). However, only cerebral amyloid angiopathy (i.e., but 
no other CVD pathology) was correlated with AD pathol-
ogy. In analyses that were adjusted for age-related neuro-
pathologies, arteriolosclerosis, atherosclerosis, cerebral 
amyloid angiopathy, and infarcts were all independently 
associated with an increased odds of AD dementia. Fur-
thermore, each of these pathologies was associated with 
impairment in multiple cognitive domains including not 
only perceptual speed but also episodic and semantic 
memory (language). The deleterious effects of CVD were 
independent of AD pathology and were present in per-
sons both with and without dementia. Thus, these data 
analyses indicate that CVD is an important determinant 
of AD dementia and relates to significant impairment in 
multiple cognitive systems in old age.
Adam M. Brickman (Columbia University, USA) focused 
on the harbingers of AD, including risk factors, biomarkers, 
and white matter hyperintensities
Prevailing hypotheses on the pathogenesis of AD include 
a cascade of biological events that emphasizes abnormal 
β-amyloid processing and tau-related neuronal and syn-
aptic dysfunction that lead to dementia. However, despite 
fairly consistent observations demonstrating the relation-
ship of vascular risk factors and frank vascular disease to 
AD, vascular factors have not been incorporated formally 
into the proposed theoretical model of AD pathogenesis 
or newly proposed research criteria for AD and its ante-
cedent conditions. The gradual accumulation of vascular 
risk factors are manifested in the brain as cerebrovascular 
small vessel disease, best visualized on T2-weighted MRI 
scans as white matter hyperintensity. He has systemati-
cally investigated the contribution of white matter hyper-
intensity to the clinical presentation of AD and tested the 
extent to which these hyperintensities interact with other 
markers of AD pathology. His research shows that these 
hyperintensities reflect pathology that is independent of 
AD pathology, conferring additive risk or contribute to 
symptom presentation. His work also shows that hyper-
intensities may interact more directly with AD pathology, 
conferring a synergistic effect on clinical outcomes.
Lenore Launer (National Institute on Aging, NIH, USA) 
described the importance of microvascular disease brain 
injury in AD and dementia
Microvascular disease is systemic, increases with age, is 
accelerated by vascular risk factors, and causes clinically 
detectable damage to multiple organs such as the retina, 
kidney, heart and brain. Microvascular disease in the 
brain refers to the narrowing and occlusion of tiny arter-
ies or arterioles that penetrate the brain cortex, reaching 
the underlying structures of the white and gray matter. 
Some microvascular lesions, such as diffuse white matter 
changes and focal microbleeds, can be seen on standard 
MRI. However, other lesions, such as microinfarcts, are 
below the limits of resolution of today’s clinical neuroim-
aging methods and can only be seen on microscopic exam-
ination of brain tissue. Recently several autopsy studies, 
including the Honolulu-Asia Aging Autopsy Study, have 
identified microinfarcts as pervasive and very prevalent in 
the brains of older demented and non-demented persons 
[63]. She emphasized that there is nothing small about the 
consequences of microvacular disease. Cumulatively, these 
microvascular lesions represent major contributors to age-
related cognitive decline and dementia. She used longitu-
dinal data (unpublished) from the Age, Gene/Environment 
susceptibility (AGES)-Reykjavik study [64] and demon-
strated that the rates of dementia and its subtypes, AD and 
vascular dementia, were nearly doubled in the 20 % of par-
ticipants who had evidence on MRI of new microbleeds. 
She described many important directions for future stud-
ies that could move the field towards new approaches 
for preventing or treating microvascular disease-related 
neurologic dysfunction including: developing standard 
neuropathological lesion measurement protocols, validat-
ing novel MRI methods to detect/measure microinfarcts, 
investigating the genetic and environmental risk factors 
leading to cerebral microvascular disease; developing tools 
to screen for possible microvascular disease and its conse-
quences, and to unravel the potential mechanisms of inter-
actions with AD lesions.
Clinton Wright (University of Miami, USA) described 
the phenotypes of subclinical cerebrovascular 
damage and age‑related cognitive outcomes learned 
from investigating a diverse urban population
We know that midlife modifiable risk factors for stroke 
and vascular disease are potent predictors of cognitive 
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decline in late life, however, many intervening factors 
confound our understanding of why this occurs. Specifics 
on the biology of aging, cellular neurodegenerative pro-
cesses, and vascular damage itself are poorly understood. 
Questions regarding the quantity, quality, and location of 
vascular injury required to take away normal cognition 
and replace it with vascular cognitive impairment are 
now only beginning to be answered. Multiple disciplines 
and scopes of understanding that range from the infini-
tesimal molecular processes of cell biology to big data and 
social networks will be needed to clarify many of these 
relationships. Population‐based studies provide insights 
into these complexities and his presentation highlighted 
examples of how structural imaging of brain changes can 
help us understand the different phenotypes. In addition, 
he discussed how commonly accepted markers of sub-
clinical brain injury relate to cognitive outcomes.
Farzaneh Sorond (Brigham and Women’s Hospital, USA) 
described ways to provide early detection of dementia 
using the neurovascular unit response as a biomarker 
for vascular functioning
CVD is an important cause of cognitive impairment and 
dementia. Intracranial small vessel disease rather than 
large strategic cortical lesions appear to be the major fac-
tor in the clinical expression of age related motor and 
cognitive decline. Brain parenchymal changes such as 
cerebral white matter hyperintensities, lacunar strokes 
and cerebral microbleeds have been identified as surro-
gate radiographic manifestations of small vessel disease. 
However, current evidence suggests that once established, 
radiographic small vessel disease is irreversible. Therefore, 
any treatment has to be directed at the vascular changes 
that precede radiographic small vessel disease. Yet, very 
few studies have examined pre-clinical cerebral vascu-
lar measures and their relationship to clinical and radio-
graphic outcomes of cerebral small vessel disease. As the 
tools to measure cerebral small vessel function become 
increasingly more sophisticated we are now well poised to 
advance our understanding of the physiological changes 
underlying cerebral small vessel disease by directly study-
ing cerebral small vessel function. The introduction of 
transcranial Doppler to measure cerebral blood flow 
velocity provided a powerful tool for non-invasive assess-
ment of cerebral vascular responses to various physiologi-
cal challenges such as motor or cognitive activation, or 
change in blood pressure and end-tidal carbon dioxide 
which we know are regulated at the level of arterioles 
or resistance vessels of the brain. Since the mechanisms 
underlying each of these vascular responses are likely dif-
ferent, they have been traditionally distinguished by dif-
ferent labels as follows: (a) Changes in cerebral blood flow 
velocity in response to sudden changes in blood pressure 
is referred to as “dynamic cerebral autoregulation”. (b) 
Changes in cerebral blood flow velocity in response to 
changes in end-tidal CO2 are referred to as “cerebral 
vasoreactivity”. (c) Changes in cerebral blood flow veloc-
ity in response to a motor or cognitive task is referred to 
as “neurovascular coupling or functional hyperemia”. In 
addition to these three functional measures, resting cere-
bral blood velocity waveform can be also used to calculate 
a “pulsatility index” which is a measure of cerebrovascular 
compliance. Using these approaches transcranial Doppler 
can provide continuous non-invasive beat-to-beat meas-
urement of the cerebral blood flow velocity in the basal 
cerebral arteries with a high temporal resolution and has 
become the most commonly utilized tool to study cer-
ebrovascular function in humans. A number of studies 
have shown that these vascular biomarkers measured by 
the transcranial Doppler are associated with radiographic 
verified small vessel disease. More recently, we and oth-
ers have shown that these vascular measures are also 
associated with deficits in motor and cognitive function. 
Using transcranial Doppler cerebral vascular measures is 
expected to allow us to shift current practice away from 
surrogate late stage brain parenchymal MRI measures to 
these vascular biomarker measurements which directly 
measure cerebral vascular functioning at an early time 
when one may be able to intervene to prevent irreversible 
neuronal injury.
Team selected discussion topics
In addition to individual participant presentations, sev-
eral pre-selected discussion topics were addressed by 
this translational team. Discussion by the team of these 
topics is briefly summarized below. In a “Biomarkers and 
Disease Monitoring” session the need for markers of VCI 
was emphasized. The transcranial Doppler measures 
were considered to be important tools for future valida-
tion. Markers of axonal and/or myelin injury (e.g., MRI 
diffusion tensor imaging) that can assess progression or 
regression of changes related to VCI need further vali-
dation. New biomarker discovery and development is 
required to help us better identify those at risk and/or 
those with prodromal dementias (e.g., from blood and/or 
CSF). In the future these new markers may tell us about 
the diagnosis, prognosis, and underlying biology of vas-
cular cognitive impairment. Early initiation and long-
term epidemiologic studies continue to be required in 
order to better understand the etiologies affecting late 
life. Clearly, epidemiologic studies of dementia progres-
sion are now required. Projecting to futuristic clinical tri-
als, it was suggested that cognitive preservation could be 
measured by molecular and cellular real-time monitoring 
connected to vascular cognitive centers that are associ-
ated with robust dementia networks.
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In a “Molecular and Cellular Disease Mechanisms” ses-
sion the beneficial vs. deleterious roles of glial cells after 
brain injury and neurodegeneration was highlighted. 
Basic work now needs to extend our understanding of 
the “bad” and “good” glial cell effects that can impact 
future effective therapeutic strategies. Cerebral endothe-
lial cells and neighboring cells comprising the perivascu-
lar niche, provides a specific microenvironment for stem 
or progenitor cells to retain their multi-lineage potential 
and self-renewal capacity. It is felt that understanding 
the mechanisms of cell–cell interactions in the perivas-
cular region would be important for developing regen-
erative therapies. We need to examine the dysfunction 
of cell–cell interactions under diseased conditions and to 
preserve the normal interactions and induce restorative 
changes after brain injury. What are the critical mecha-
nisms that link risk factors (e.g., stroke, hypertension, 
atherosclerosis and Type 2 Diabetes) to increase brain 
vulnerability into a degenerating condition leading to 
dementia? Experimental models that demonstrate these 
interactions can be used to help study these mechanisms. 
Also, we require blood brain barrier experimental models 
and new approaches for clinical assessment of BBB func-
tion. It appears that the highest impact can be obtained 
by focusing on the initial stages in the process preced-
ing dementia (e.g., early effects of co-morbidities on 
neuronal, glial, and cerebrovascular regulation and their 
relationship to high levels of brain amyloid, oxidative 
stress, matrix degrading enzymes and vascular perme-
ability and axonal disruption). Questions were raised on 
expression of cognitive phenotypes for vascular damage 
in their most recognizable forms and how these pheno-
types can be distinguished from normal aging and neu-
rodegeneration. It was suggested that multiple therapies 
might be appropriate but that translational experimental 
approaches will be required to provide proof of principle 
for a combination of agents to intervene in this process 
which, of course, will require a more detailed under-
standing of combined Vascular-AD pathology.
Finally, in a session on “Funding, Vascular Interventions 
and Animal Modeling”, participants were interested in 
collaboration opportunities, in identifying creative ways 
to support and expand collaborative work together and 
in translating experimental and/or epidemiological find-
ings into treatment. These continued ongoing discus-
sions and collaborative work will be the subject of report 
updates and group discussions at our future workshops. 
It was considered important to develop mechanism 
based therapies with focused therapeutic approaches that 
really target the processes in the cerebral vasculature and 
downstream from there to subsequent effects that affect 
cognitive processing (i.e., not just risk factor manage-
ment). It was emphasized that current animal models 
for AD show translational failure because they are cross-
sectional and focus on single highly overexpressed fac-
tors. This differs significantly from human conditions. 
Animal models must take into account important aspects 
of human AD, such as aging, CVD, and gender. Aging 
is the strongest risk factor for AD, but we lack a valid 
animal model to study the effects of age on AD. In spo-
radic AD, the prevalence of vascular risk factors is high, 
and ignoring these vascular-disease factors when study-
ing experimental AD has hampered translation. Gender 
strongly affects outcome in AD models, but this is com-
monly ignored and leads to erroneous interpretations, 
and thus to translation. Studying long-term, longitudi-
nal changes are very important. Human AD is a chronic 
disorder with an asymptomatic phase of 20–30  years. 
Although longitudinal studies in humans are time con-
suming, animal models can speed this up significantly. 
Translational animal models will allow us to study life-
time effects of aging, cardiovascular-metabolic changes, 
gender, and CVD on parameters known to be affected 
in human sporadic AD. For example, genetically and/or 
diet modified rodents can be utilized and subjected to 
in vivo brain administrations of Aβ followed by cognition 
testing and later brain atrophy and altered connectiv-
ity measurements, including post-mortem brain pathol-
ogy and mechanistic histology-immunohistochemistry 
approaches that monitor inflammation, amyloid pathol-
ogy, cellular and axonal injury and synaptic loss. The rel-
evant imaging and fluid molecular data discussed at this 
workshop and by many others will need validation for use 
as biomarkers for future clinical use.
‘Think Tank’ VCI workshop: summary and future 
steps
Vascular disease was once considered the primary cause 
of age-related dementia [55–57]. Then this “vascular-cen-
tric’ thinking in AD had been ignored for a long period. 
Now we have returned back to this thinking based on 
much more data and a better understanding of the car-
diovascular and metabolic contributions to cognitive loss 
with even greater focus on research emphasis to elucidate 
specific pathophysiologic mechanisms that contribute 
to dementia phenotypes and neuropathologic outcomes 
[65–69]. There have been major statements reviewed by 
global health groups [57, 58], diagnostic statements made 
regarding VCI [50, 70, 71] and other workshop/sympo-
sium summaries of this debate [72, 73]. Here in our ‘Think 
Tank’ workshop we represented expertise in neurology, 
neuropathology, epidemiology, neuroscience, preclini-
cal science, and pharmacology, among other disciplines. 
Our focus was on CVD (including vascular and metabolic 
changes) and its involvement in the progression of cogni-
tive impairment to dementia. Thus, we actively discussed 
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or presented aspects of dementia in relationship to hyper-
tension, atherosclerosis-carotid stenosis, diabetes, obe-
sity, lipids, nutrition and chronic HIV infection. Imaging, 
cerebrovascular, behavioral and circulation biomarker 
development strategies that might be useful for diagnostic 
and prognostic purposes were also addressed. Epidemio-
logical associations with vascular and metabolic risk fac-
tors were significant points of discussion. The interaction 
between cerebrovascular and metabolic-diet conditions 
and neurodegenerative disease was discussed in detail 
by this translational team. Given the success of this first 
workshop, The Leo and Anne Albert Charitable Trust has 
decided to support future meetings on a biannual basis 
in order to continue formal discussions/debates, address 
new knowledge/technology, continue and build collabora-
tions including invitations to new participants. Based on 
the changing emphasis and new knowledge and our dis-
cussions at this meeting, we decided that our future ‘think 
tank’ workshops will refer to the spectrum of vascular 
and AD contributions to dementia as Vascular-Alzheimer 
Spectrum (VAS) Disorders [74]. All coauthors agreed to 
cooperate/collaborate together on VAS Disorders now 
and to bring together/consult experts in the future for our 
next workshop on VAS Disorders in 2017.
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